French allergy company DBV takes first step towards 2012 IPO
This article was originally published in Scrip
Executive Summary
Allergy treatment specialist DBV Technologies has shown its first official sign of intent to make an initial public offering on the NYSE Euronext exchange this year with the filing of its "Document de Base" with the French financial regulator, the Autorité des marchés financiers (AMF). The precise timing of the IPO will depend on market conditions and is subject to the approval of the AMF.